Clinical Trials Browser

Phase 1/2 × INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × Clear all

Non-Muscle Invasive Bladder Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

Phase 1/2 Not yet recruiting

120 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

Phase 1/2 Recruiting

32 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

350 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05544552 2026-01-12

SURF301

Phase 1/2 Active not recruiting

310 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT02138734 2025-10-16

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

596 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06800963 2025-05-16

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Not yet recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04690699 2024-10-24

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

Phase 1/2 Terminated

4 enrolled 6 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Phase 1/2 Terminated

12 enrolled 13 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

NCT03636256 2023-08-14

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Phase 1/2 Completed

36 enrolled 18 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

NCT00318643 2021-10-29

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Phase 1/2 Completed

27 enrolled 14 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02009332 2021-06-08

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Phase 1/2 Completed

21 enrolled 11 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT03560479 2020-08-19

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Phase 1/2 Unknown

52 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT02007005 2015-05-06

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer

Phase 1/2 Completed

37 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Clinical Trials

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

TroFuse-027

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

SURF301

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Evaluation of NanoDoce® in Participants With Urothelial Carcinoma

Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer